Tis­sue re­gen­er­a­tion biotech rais­es $26M Se­ries A to push to­ward clin­i­cal tri­als

A Mary­land biotech led by an Army vet­er­an and for­mer West Point pro­fes­sor has raised an ad­di­tion­al $26 mil­lion to move its tar­get­ed ther­a­peu­tics plat­form in­to hu­man tri­als.

Ther­adap­tive is fo­cused on de­vel­op­ing tis­sue re­gen­er­a­tion ther­a­pies in or­tho­pe­dics, an area of in­ter­est to founder and CEO Luis Al­varez, who saw ser­vice mem­bers have de­layed am­pu­ta­tions dur­ing his time in the Army. He lat­er went back to MIT to find a so­lu­tion to that prob­lem — work­ing on tis­sue re­gen­er­a­tion, which re­sult­ed in a spin­out of Ther­adap­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER